Syncope. Syncope and collapse
Conditions
Interventions
Intervention 1: Intervention group: Atomoxetine 20 mg daily, taken orally, for 2 weeks and 40 mg daily for another 2 weeks, if tolerated. The pills will be sealed in 2 envelopes for each 2-week perio
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
10 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients who come to the Tehran Heart Center with a complaint of syncope or pre-syncope with the clinical diagnosis of vasovagal syncope or have undergone tilt test, if needed, and experienced at least 3 syncopal episodes in the past 3 months.
Exclusion criteria
Exclusion criteria: Age under 10 or over 70 years old History of uncontrolled blood pressure History of structural heart disease History of epilepsy History of closed angle glaucoma History of diabetes mellitus History of coronary artery disease Ejection fraction < 50% Use of monoamine oxidase inhibitors (MAOIs) Use of selective serotonin reuptake inhibitors (SSRIs) Use of anticonvulsants
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of (pre-)syncopal episodes. Timepoint: Follow-up visit at month 1 and 3. Method of measurement: Based on history and physical exam. | — |
Secondary
| Measure | Time frame |
|---|---|
| Anxiety. Timepoint: Follow-up visit on month 3. Method of measurement: Hospital Anxiety and Depression Scale Questionnaire.;Depression. Timepoint: Follow-up visit on month 3. Method of measurement: Hospital Anxiety and Depression Scale Questionnaire.;Physical quality of life. Timepoint: Follow-up visit on month 3. Method of measurement: 36-Item Short Form Survey Questionnaire.;Mental quality of life. Timepoint: Follow-up visit on month 3. Method of measurement: 36-Item Short Form Survey Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMasih Tajdini
Tehran University of Medical Sciences
Outcome results
None listed